Delphia (USA)’s AnaptysBio ANAB Stock Holding History

Delphia (USA)’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-9,433	Closed	-$233K	–	389
2022 Q1	$233K	Buy	+9,433	New	+$285K	0.17%	225

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Delphia (USA)'s ANAB Position: Q2 2022 in Review

Delphia (USA) sold out of AnaptysBio (ANAB) in Q2 2022, closing a stake of 9,433 shares — an estimated $233K sold.

Delphia (USA) first reported a position in ANAB in Q1 2022 and held it in 1 quarter. The position peaked at $233K in Q1 2022. 124 funds tracked by Wall St. Rank hold ANAB as of Q2 2022.

Delphia (USA) reported no remaining AnaptysBio position as of Q2 2022 after selling out during the quarter.
Delphia (USA) sold 9,433 AnaptysBio shares in Q2 2022, an estimated $233K.
Delphia (USA) first reported a position in AnaptysBio in Q1 2022 and held it in 1 quarter.
Delphia (USA)'s AnaptysBio position peaked at $233K in Q1 2022.
124 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2022.

Based on Delphia (USA)'s 13F filing for Q2 2022, filed 15 Aug 2022.